J&J gets FDA panel backing for simeprevir in hot race for hep C drug

Johnson & Johnson ($JNJ) is out of the gate in the horse race that is shaping up around interferon-free cocktails for treating hepatitis C. An FDA panel voted 19-0 to recommend its simeprevir, an NS3/4A protease inhibitor that promises to treat the most common genotype of chronic hepatitis C. But the same panel will meet today on the rival from Gilead Sciences ($GILD), which has been touted as the class leader. And AbbVie ($ABBV) and Bristol-Myers Squibb ($BMY) are in the race as well. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.